Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Expression of prostate-specific membrane antigen in normal and malignant human tissues.

Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP.

World J Surg. 2006 Apr;30(4):628-36.

PMID:
16555021
2.

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB.

Cancer Res. 1999 Jul 1;59(13):3192-8.

3.

Prostate-specific membrane antigen expression in normal and malignant human tissues.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C.

Clin Cancer Res. 1997 Jan;3(1):81-5.

4.

Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.

Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB.

Cancer. 2000 Jan 15;88(2):407-15.

PMID:
10640975
5.

Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids.

Troyer JK, Beckett ML, Wright GL Jr.

Int J Cancer. 1995 Sep 4;62(5):552-8.

PMID:
7665226
6.
7.
8.

PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.

Antunes AA, Reis ST, Leite KR, Real DM, Sousa-Canavez JM, Camara-Lopes LH, Dall'Oglio MF, Srougi M.

Int Braz J Urol. 2013 Sep-Oct;39(5):649-56. doi: 10.1590/S1677-5538.IBJU.2013.05.06.

9.

Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies.

Ben Jemaa A, Bouraoui Y, Sallami S, Banasr A, Ben Rais N, Ouertani L, Nouira Y, Horchani A, Oueslati R.

J Exp Clin Cancer Res. 2010 Dec 28;29:171. doi: 10.1186/1756-9966-29-171.

10.

The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Ristau BT, O'Keefe DS, Bacich DJ.

Urol Oncol. 2014 Apr;32(3):272-9. doi: 10.1016/j.urolonc.2013.09.003. Epub 2013 Dec 8. Review.

12.
13.

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW.

Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.

14.

Prostate-specific membrane antigen-based imaging.

Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST.

Urol Oncol. 2013 Feb;31(2):144-54. doi: 10.1016/j.urolonc.2012.04.016. Epub 2012 May 31. Review.

15.

Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.

Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA.

Int J Cancer. 2003 Nov 1;107(2):323-9.

16.

High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.

Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T.

Prostate. 2011 Feb 15;71(3):281-8. doi: 10.1002/pros.21241. Epub 2010 Aug 31.

PMID:
20809553
17.

Re: PGC and PSMA in prostate cancer diagnosis: tissue analysis from biopsy samples.

Wiwanitkit S.

Int Braz J Urol. 2014 Mar-Apr;40(2):285; author reply 286. doi: 10.1590/S1677-5538.IBJU.2014.02.24. No abstract available.

18.

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R.

Urology. 1996 Aug;48(2):326-34.

PMID:
8753752
19.

Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.

Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R.

J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):555-63. Review.

PMID:
25620167
20.

PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.

Ben Jemaa A, Bouraoui Y, Sallami S, Banasr A, Nouira Y, Oueslati R.

Pathol Biol (Paris). 2014 Jun;62(3):129-36. doi: 10.1016/j.patbio.2014.02.012. Epub 2014 Apr 16.

PMID:
24745345

Supplemental Content

Support Center